AmpliPhi Adds Two Board Members
This article was originally published in Scrip
Executive Summary
AmpliPhi Biosciences Corp. has appointed Vijay B. Samant and Paul C. Grint to its board as non-executive directors. Samant is currently president and CEO of Vical, Inc and prior to this he held various positions at Merck & Co. He was CEO of the Merck Vaccine Division, vice president (VP) of vaccine operations, VP of business affairs and director of materials management. Samant also served on the board of various companies including Raptor Pharmaceuticals and BioMarin. Grint is president and CEO of Regulus Therapeutics Inc. and before this he was president of Cerexa Inc. Previously he served in senior management roles at Forest Research Institute, Pfizer and IDEC Pharmaceuticals.
You may also be interested in...
Text Mining And Machine Reading: The Answer To Pharma's R&D Data Mountain?
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Adherence Issues Add Weight To Digital Trials Push
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
Appointments: Five Prime, Depomed, Gilead, Arix Bioscience and Corbus
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.